Loading...
•
Sep 30
Sanara MedTech Q3 2025 Earnings Report
Reported a 22% increase in net revenue and achieved positive net income from continuing operations in Q3 2025.
Key Takeaways
Sanara MedTech posted strong Q3 2025 results, highlighted by significant revenue growth and improved profitability driven by soft tissue repair product sales.
Net revenue rose to $26.3 million, driven by growth in soft tissue repair product sales.
Net income from continuing operations reached $0.8 million, a reversal from the prior year's loss.
Adjusted EBITDA more than doubled to $4.9 million from $2.6 million in Q3 2024.
Gross margin improved to 93% due to higher-margin product mix.
Sanara MedTech
Sanara MedTech
Sanara MedTech Revenue by Segment
Sanara MedTech Revenue by Geographic Location
Revenue by Segment
Soft tissue repair Revenue
CapyFin.comBone fusion products Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Sanara expects to continue executing its commercial strategy while investing in its core surgical business for sustainable revenue growth and profitability.
Positive Outlook
- Focused strategy on core surgical business post-THP exit.
- Strengthening distribution network with independent reps.
- Continued penetration into new and existing healthcare facilities.
- Increased surgeon adoption driving sales.
- Operational efficiencies expected from strategic realignment.
Challenges Ahead
- Losses from discontinued THP operations impacted overall bottom line.
- Higher interest expense weighed on net income.
- Continued R&D and SG&A spending pressuring margins.
- Equity method investments generating losses.
- Limited international revenue diversification.
Revenue & Expenses
Visualization of income flow from segment revenue to net income